White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

The White House has announced a new 'most-favored nation' (MFN) pricing deal with EMD Serono for a fertility drug, aiming to expand access to in vitro fertilization (IVF) and lower treatment costs1 3 7.

EMD Serono agreed to MFN pricing on new and existing drugs sold to state Medicaid programs, joining recent similar deals made with Pfizer and AstraZeneca under the Trump administration1 2 13.

President Trump signed an executive order in May directing the Department of Health and Human Services (HHS) to establish MFN price targets for branded drugs (with no generic/biosimilar competition) sold to Medicare and Medicaid. These targets represent the lowest price paid in any OECD country meeting specific GDP criteria4 11 14.

Drug manufacturers have been ordered to extend MFN pricing to all Medicaid enrollees and guarantee MFN pricing on newly launched drugs for Medicare, Medicaid, and commercial payers, with binding commitments due by late September10 8.

Manufacturers must participate in direct-to-consumer or direct-to-business models to ensure all Americans can purchase at MFN prices, which are already given to some third-party payers10.

Recent agreements require pharmaceutical companies like Pfizer to offer MFN drug prices nationally to state Medicaid programs, as well as deep discounts when selling directly to American patients13.

The administration's focus remains on lowering drug costs broadly and negotiating with major manufacturers; latest steps are being implemented through executive orders and agency-directed initiatives4 10.

As of the latest updates, there has been no direct public disclosure of specific outcomes regarding FDA vouchers or GLP-1 negotiations within the news cycle, indicating these may be ongoing policy components but lacking new milestone announcements in the referenced period.